Literature DB >> 25737615

Progesterone vaginal ring for luteal support.

Laurel Stadtmauer1, Kay Waud1.   

Abstract

Progesterone supplementation is universally used and has been shown to be beneficial in supplementation of the luteal phase in IVF. There are multiple options and the most commonly used include intramuscular and vaginal progesterone. A progesterone vaginal ring is a novel system for luteal support with advantages of controlled release with less frequent dosing. This review examines options for progesterone luteal support focusing on the rationale for a progesterone vaginal ring. Pub-med search of the literature. A weekly vaginal ring, although not yet FDA approved, is an effective and safe alternative for luteal supplementation in IVF. Large prospective clinical trials are needed to determine the best protocols for replacement cycles.

Entities:  

Keywords:  IVF; Luteal support; Progesterone supplementation; Progesterone vaginal ring

Year:  2014        PMID: 25737615      PMCID: PMC4342373          DOI: 10.1007/s13224-014-0634-0

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  28 in total

1.  Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation.

Authors:  F Zegers-Hochschild; J P Balmaceda; C Fabres; V Alam; A Mackenna; E Fernández; I M Pacheco; M S Sepúlveda; S Chen; C Borrero; E Borges
Journal:  Hum Reprod       Date:  2000-10       Impact factor: 6.918

Review 2.  Luteal phase support for frozen embryo transfer cycles: intramuscular or vaginal progesterone?

Authors:  Robert F Casper
Journal:  Fertil Steril       Date:  2014-02-01       Impact factor: 7.329

3.  Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure.

Authors:  C Bourgain; P Devroey; L Van Waesberghe; J Smitz; A C Van Steirteghem
Journal:  Hum Reprod       Date:  1990-07       Impact factor: 6.918

4.  Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone.

Authors:  J L Pouly; S Bassil; R Frydman; B Hedon; B Nicollet; Y Prada; J M Antoine; R Zambrano; J Donnez
Journal:  Hum Reprod       Date:  1996-10       Impact factor: 6.918

5.  Pilot study evaluating a progesterone vaginal ring for luteal-phase replacement in donor oocyte recipients.

Authors:  Laurel Stadtmauer; Diane D Harrison; Jeannine Boyd; Silvina Bocca; Sergio Oehninger
Journal:  Fertil Steril       Date:  2008-11-06       Impact factor: 7.329

6.  The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix.

Authors:  C Albano; G Grimbizis; J Smitz; H Riethmüller-Winzen; T Reissmann; A Van Steirteghem; P Devroey
Journal:  Fertil Steril       Date:  1998-08       Impact factor: 7.329

7.  Direct transport of progesterone from vagina to uterus.

Authors:  E Cicinelli; D de Ziegler; C Bulletti; M G Matteo; L M Schonauer; P Galantino
Journal:  Obstet Gynecol       Date:  2000-03       Impact factor: 7.661

Review 8.  An update of luteal phase support in stimulated IVF cycles.

Authors:  H M Fatemi; B Popovic-Todorovic; E Papanikolaou; P Donoso; P Devroey
Journal:  Hum Reprod Update       Date:  2007-07-11       Impact factor: 15.610

9.  Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study.

Authors:  R A Miles; R J Paulson; R A Lobo; M F Press; L Dahmoush; M V Sauer
Journal:  Fertil Steril       Date:  1994-09       Impact factor: 7.329

10.  Assisted reproductive technology surveillance -- United States, 2010.

Authors:  Saswati Sunderam; Dmitry M Kissin; Sara Crawford; John E Anderson; Suzanne G Folger; Denise J Jamieson; Wanda D Barfield
Journal:  MMWR Surveill Summ       Date:  2013-12-06
View more
  1 in total

1.  Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep.

Authors:  Herman Weiss; Bridget Martell; Ginger D Constantine; Sarah M Davis; Justin D Vidal; Philip R Mayer; Martin Doorbar; David R Friend
Journal:  Drug Deliv Transl Res       Date:  2019-10       Impact factor: 4.617

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.